array(40) {
  [0]=>
  string(4) "3506"
  ["article_id"]=>
  string(4) "3506"
  [1]=>
  string(77) "1st World Congress on Women’s Health Innovations and Inventions (WHII)"
  ["article_title"]=>
  string(77) "1st World Congress on Women’s Health Innovations and Inventions (WHII)"
  [2]=>
  string(155) "The 1st World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs will be held on July 9-11, 2019 in Tel Aviv, Isra"
  ["short_description"]=>
  string(155) "The 1st World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs will be held on July 9-11, 2019 in Tel Aviv, Isra"
  [3]=>
  string(533) "The 1st World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs will be held on July 9-11, 2019 in Tel Aviv, Israel.We invite you to participate in the first Women’s Health Congress bringing technology and science together to address the unmet needs.We will discuss the unmet needs of Women’s Health with physicians, other healthcare providers, technology experts and companies involved in developing those future technologies. The Congress will explore fuel, spark…"
  ["description"]=>
  string(533) "The 1st World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs will be held on July 9-11, 2019 in Tel Aviv, Israel.We invite you to participate in the first Women’s Health Congress bringing technology and science together to address the unmet needs.We will discuss the unmet needs of Women’s Health with physicians, other healthcare providers, technology experts and companies involved in developing those future technologies. The Congress will explore fuel, spark…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(117) "
https://www.pharmiweb.com/event/1st-world-congress-on-women-s-health-innovations-and-inventions-whii                "
  ["blog_url"]=>
  string(117) "
https://www.pharmiweb.com/event/1st-world-congress-on-women-s-health-innovations-and-inventions-whii                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:49:32"
  ["create_at"]=>
  string(19) "2019-07-02 11:49:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3709"
  ["article_id"]=>
  string(4) "3709"
  [1]=>
  string(61) "Novartis multiple sclerosis product Gilenya approved in China"
  ["article_title"]=>
  string(61) "Novartis multiple sclerosis product Gilenya approved in China"
  [2]=>
  string(150) "Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS d"
  ["short_description"]=>
  string(150) "Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS d"
  [3]=>
  string(571) "
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment 
&#nl
The post Novartis multiple sclerosis product Gilenya approved in China appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(571) "
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment 
&#nl
The post Novartis multiple sclerosis product Gilenya approved in China appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(114) "https://www.pharmaceutical-business-review.com/news/novartis-multiple-sclerosis-product-gilenya-approved-in-china/"
  ["blog_url"]=>
  string(114) "https://www.pharmaceutical-business-review.com/news/novartis-multiple-sclerosis-product-gilenya-approved-in-china/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3710"
  ["article_id"]=>
  string(4) "3710"
  [1]=>
  string(100) "Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease"
  ["article_title"]=>
  string(100) "Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease"
  [2]=>
  string(150) "Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It"
  ["short_description"]=>
  string(150) "Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It"
  [3]=>
  string(598) "
Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved 
&#nl
The post Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(598) "
Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved 
&#nl
The post Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/celgene-otezla-behcets-disease/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/celgene-otezla-behcets-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3711"
  ["article_id"]=>
  string(4) "3711"
  [1]=>
  string(86) "Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus"
  ["article_title"]=>
  string(86) "Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus"
  [2]=>
  string(150) "TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cel"
  ["short_description"]=>
  string(150) "TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cel"
  [3]=>
  string(628) "
TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of 
&#nl
The post Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(628) "
TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of 
&#nl
The post Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/transgene-receives-mhra-approval-for-clinical-trial-of-next-generation-oncolytic-virus/"
  ["blog_url"]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/transgene-receives-mhra-approval-for-clinical-trial-of-next-generation-oncolytic-virus/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3712"
  ["article_id"]=>
  string(4) "3712"
  [1]=>
  string(90) "LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome"
  ["article_title"]=>
  string(90) "LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome"
  [2]=>
  string(154) "“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Pha"
  ["short_description"]=>
  string(154) "“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Pha"
  [3]=>
  string(640) "
“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome 
&#nl
The post LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(640) "
“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome 
&#nl
The post LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(143) "https://www.pharmaceutical-business-review.com/news/lifemax-receives-rare-pediatric-disease-designation-for-lm-030-to-treat-netherton-syndrome/"
  ["blog_url"]=>
  string(143) "https://www.pharmaceutical-business-review.com/news/lifemax-receives-rare-pediatric-disease-designation-for-lm-030-to-treat-netherton-syndrome/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3713"
  ["article_id"]=>
  string(4) "3713"
  [1]=>
  string(85) "Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate"
  ["article_title"]=>
  string(85) "Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate"
  [2]=>
  string(155) "The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopath"
  ["short_description"]=>
  string(155) "The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopath"
  [3]=>
  string(629) "
The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure 
&#nl
The post Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(629) "
The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure 
&#nl
The post Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/boehringer-bridge-biotherapeutics-ipf/"
  ["blog_url"]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/boehringer-bridge-biotherapeutics-ipf/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3714"
  ["article_id"]=>
  string(4) "3714"
  [1]=>
  string(76) "AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs"
  ["article_title"]=>
  string(76) "AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs"
  [2]=>
  string(155) "AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superio"
  ["short_description"]=>
  string(155) "AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superio"
  [3]=>
  string(611) "
AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superior Court of California County of 
&#nl
The post AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(611) "
AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superior Court of California County of 
&#nl
The post AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/ahf-calls-on-gilead-to-set-up-fund-for-victims-harmed-by-its-tdf-based-drugs/"
  ["blog_url"]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/ahf-calls-on-gilead-to-set-up-fund-for-victims-harmed-by-its-tdf-based-drugs/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3715"
  ["article_id"]=>
  string(4) "3715"
  [1]=>
  string(74) "PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema"
  ["article_title"]=>
  string(74) "PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema"
  [2]=>
  string(150) "In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 cli"
  ["short_description"]=>
  string(150) "In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 cli"
  [3]=>
  string(629) "
In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to 
&#nl
The post PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(629) "
In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to 
&#nl
The post PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(127) "https://www.pharmaceutical-business-review.com/news/puretech-acquires-new-clinical-stage-programme-lyt-100-to-treat-lymphedema/"
  ["blog_url"]=>
  string(127) "https://www.pharmaceutical-business-review.com/news/puretech-acquires-new-clinical-stage-programme-lyt-100-to-treat-lymphedema/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3716"
  ["article_id"]=>
  string(4) "3716"
  [1]=>
  string(69) "FDA approves Merck’s Recarbrio to treat complicated infections"
  ["article_title"]=>
  string(69) "FDA approves Merck’s Recarbrio to treat complicated infections"
  [2]=>
  string(150) "The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including py"
  ["short_description"]=>
  string(150) "The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including py"
  [3]=>
  string(553) "
The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by 
&#nl
The post FDA approves Merck’s Recarbrio to treat complicated infections appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(553) "
The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by 
&#nl
The post FDA approves Merck’s Recarbrio to treat complicated infections appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(91) "https://www.pharmaceutical-business-review.com/news/merck-recarbrio-complicated-infections/"
  ["blog_url"]=>
  string(91) "https://www.pharmaceutical-business-review.com/news/merck-recarbrio-complicated-infections/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3717"
  ["article_id"]=>
  string(4) "3717"
  [1]=>
  string(77) "Astellas signs licensing deal for Frequency’s regenerative drug FX-322"
  ["article_title"]=>
  string(77) "Astellas signs licensing deal for Frequency’s regenerative drug FX-322"
  [2]=>
  string(150) "As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be respons"
  ["short_description"]=>
  string(150) "As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be respons"
  [3]=>
  string(576) "
As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation 
&#nl
The post Astellas signs licensing deal for Frequency’s regenerative drug FX-322 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(576) "
As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation 
&#nl
The post Astellas signs licensing deal for Frequency’s regenerative drug FX-322 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/astellas-frequency-fx-322-deal/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/astellas-frequency-fx-322-deal/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3718"
  ["article_id"]=>
  string(4) "3718"
  [1]=>
  string(86) "Kite to bolster cell therapy manufacturing capabilities with new viral vector facility"
  ["article_title"]=>
  string(86) "Kite to bolster cell therapy manufacturing capabilities with new viral vector facility"
  [2]=>
  string(155) "The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, incl"
  ["short_description"]=>
  string(155) "The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, incl"
  [3]=>
  string(693) "
The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available chimeric 
&#nl
The post Kite to bolster cell therapy manufacturing capabilities with new viral vector facility appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(693) "
The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available chimeric 
&#nl
The post Kite to bolster cell therapy manufacturing capabilities with new viral vector facility appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/kite-to-bolster-cell-therapy-manufacturing-capabilities-with-new-viral-vector-facility/"
  ["blog_url"]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/kite-to-bolster-cell-therapy-manufacturing-capabilities-with-new-viral-vector-facility/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:51:19"
  ["create_at"]=>
  string(19) "2019-07-22 17:51:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3811"
  ["article_id"]=>
  string(4) "3811"
  [1]=>
  string(45) "2nd Annual Hemophilia Drug Development Summit"
  ["article_title"]=>
  string(45) "2nd Annual Hemophilia Drug Development Summit"
  [2]=>
  string(150) "Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Develo"
  ["short_description"]=>
  string(150) "Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Develo"
  [3]=>
  string(515) "Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.&#nlFuelled by current investment in the space and novel therapeutic strategies to improve current stan…"
  ["description"]=>
  string(515) "Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.&#nlFuelled by current investment in the space and novel therapeutic strategies to improve current stan…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "59"
  ["rss_id"]=>
  string(2) "59"
  [14]=>
  string(94) "
https://www.pharmiweb.com/event/2nd-annual-hemophilia-drug-development-summit                "
  ["blog_url"]=>
  string(94) "
https://www.pharmiweb.com/event/2nd-annual-hemophilia-drug-development-summit                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-22 17:53:40"
  ["create_at"]=>
  string(19) "2019-07-22 17:53:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}